TCT 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Shows Low Five-Year Event Rates in BIOFLOW-II RCT and BIOFLOW-III Registry
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
DENVER, United States and BUELACH, Switzerland, November 2, 2017 - BIOTRONIK's Orsiro1 drug-eluting stent (DES) demonstr…
Data presented during the TCT congress on BIOTRONIK’s Magmaris1 RMS provide further evidence on its continued safety and…
BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical pe…
BIOTRONIK’s exclusive rate responsive technology, Closed Loop Stimulation (CLS) has shown to reduce fainting in pacemake…
Cardiology experts will present conclusive results from various BIOTRONIK studies at the European Society of Cardiology’…
BIOTRONIK’s highest performing cardiac resynchronization therapy defibrillator (CRT-D) is now available in Japan. With s…
BIOTRONIK’s Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared to a polymeric scaffold*.…
Der resorbierbare Magnesium-Scaffold Magmaris zeigt ein reduziertes Risiko für die Bildung von Thromben im Vergleich zum…
Twenty-four month data from the BIOSOLVE-II study reveal the long-term safety, efficacy and stability of BIOTRONIK’s Mag…
BIOTRONIK has announced the European launch of a new lead for tachycardia therapy that features a helical design for inc…